J Kevin Buchi
CIK 1209726 · Chief Executive Officer · last filed 2026-09-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CEPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
FRAZER, PA 19355
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AMRX | Director | 189,021 | $21.27 | $4.02M | $0 | 14 | 2026-09-21 |
| BNTC | Director | 103,910 | $8.69 | $902.5K | $0 | 9 | 2025-12-03 |
| Ampio Pharmaceuticals, Inc. (AMPE) Delisted | Director | 7,343 | $0.18 | $1.3K | $39.0K | 6 | 2023-06-13 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 0 | $38.22 | $0 | $0 | 6 | 2021-12-29 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 4,167 | $0.87 | $3.6K | $0 | 2 | 2021-05-06 |
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | Chief Executive Officer | — | — | — | $0 | 1 | 2019-10-25 |
| Impax Laboratories, LLC (IPXL) Delisted | Director | 11,301 | — | — | $0 | 2 | 2017-05-17 |
| STEMLINE THERAPEUTICS INC (STML) Delisted | Director | 23,772 | — | — | $5.0K | 3 | 2015-06-25 |
| Alexza Pharmaceuticals Inc. (ALXA) Delisted | Director | — | — | — | $0 | 1 | 2015-06-25 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Director | — | — | — | $0 | 2 | 2015-06-08 |
| TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted | President & CEO | 330,714 | — | — | $2.21M | 8 | 2015-03-30 |
| CEPHALON INC (CEPH) Delisted | Chief Executive Officer | 0 | — | — | -$6.89M | 28 | 2011-10-17 |
| ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted | Director | 0 | — | — | $0 | 7 | 2008-04-03 |
Recent Filings · Page 8 of 10
92 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-12-02 | CEPHALON INC (CEPH) Delisted | Tax (F) | −1,241 | -$68.7K | EDGAR |
| 2009-06-29 | CEPHALON INC (CEPH) Delisted | Gift (G) | −453 | $0 | EDGAR |
| 2008-12-23 | CEPHALON INC (CEPH) Delisted | Gift (G) | −140 | $0 | EDGAR |
| 2008-12-22 | CEPHALON INC (CEPH) Delisted | Tax (F) | −1,616 | -$125.2K | EDGAR |
| 2008-12-17 | CEPHALON INC (CEPH) Delisted | Tax (F) | −1,939 | -$148.0K | EDGAR |
| 2008-12-16 | CEPHALON INC (CEPH) Delisted | Tax (F) | −1,616 | -$121.7K | EDGAR |
| 2008-12-12 | CEPHALON INC (CEPH) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
| 2008-12-04 | CEPHALON INC (CEPH) Delisted | Sell (S) | −15,000 | -$1.11M | EDGAR |
| 2008-12-03 | CEPHALON INC (CEPH) Delisted | Tax (F) | −1,616 | -$111.3K | EDGAR |
| 2008-04-03 | ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted | U | −11,253 | -$26.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.